Cheng Isaac T, Meng Huan, Li Martin, Li Edmund K, Wong Priscilla C, Lee Jack, Yan Bryan P, Lee Alex P W, So Ho, Tam Lai-Shan
Department of Medicine and Therapeutics, Prince of Wales Hospital, The Chinese University of Hong Kong, Shatin, Hong Kong SAR, China.
Jockey Club School of Public Health and Primary Care, The Chinese University of Hong Kong, Hong Kong, Hong Kong SAR, China.
Front Med (Lausanne). 2022 Jul 8;9:932696. doi: 10.3389/fmed.2022.932696. eCollection 2022.
Whether calprotectin could play a role in augmenting cardiovascular (CV) risk in patients with psoriatic arthritis (PsA) remains uncertain. The aim of this study is to elucidate the association between serum calprotectin level and subclinical atherosclerosis in patient with PsA.
Seventy-eight PsA patients (age: 52 ± 10 years, 41 [52.6%] male) without CV disease were recruited into this cross-sectional study. Carotid intima-media thickness (cIMT) and the presence of plaque were determined by high-resolution ultrasound. Calprotectin levels in serum were quantified by enzyme-linked immunosorbent assay. The variables associated with the presence of carotid plaque (CP) were selected from the least absolute shrinkage and selection operator (LASSO) regression analysis.
29/78 (37.2%) of patient had carotid plaque (CP+ group). Serum calprotectin level was significantly higher in the CP+ group (CP- group: 564.6 [329.3-910.5] ng/ml; CP+ group: 721.3 [329.3-910.5] ng/ml, = 0.005). Serum calprotectin level correlated with PsA disease duration (rho = 0.280, = 0.013) and mean cIMT (rho = 0.249, = 0.038). Using LASSO regression analysis, the levels of Ln-calprotectin (OR: 3.38, 95% CI [1.37, 9.47]; = 0.026) and PsA disease duration (OR: 1.09, 95% CI [1.01, 1.18]; = 0.013) were screened out from a total of 19 variables. The model in predicting the presence of CP was constructed by Ln-calprotectin and PsA disease duration with an area under the receiver-operating characteristic (ROC) curve of 0.744, (95 CI% [0.59, 0.80], = 0.037).
Serum calprotectin level is associated with the presence of CP in PsA. Further studies are required to confirm whether this pathway is associated with CV events in PsA.
钙卫蛋白是否会在银屑病关节炎（PsA）患者中增加心血管（CV）风险方面发挥作用仍不确定。本研究的目的是阐明PsA患者血清钙卫蛋白水平与亚临床动脉粥样硬化之间的关联。
78例无心血管疾病的PsA患者（年龄：52±10岁，41例[52.6%]为男性）被纳入这项横断面研究。通过高分辨率超声测定颈动脉内膜中层厚度（cIMT）和斑块的存在情况。采用酶联免疫吸附测定法对血清中的钙卫蛋白水平进行定量。与颈动脉斑块（CP）存在相关的变量从最小绝对收缩和选择算子（LASSO）回归分析中选取。
29/78（37.2%）的患者有颈动脉斑块（CP+组）。CP+组的血清钙卫蛋白水平显著更高（CP-组：564.6[329.3 - 910.5]ng/ml；CP+组：721.3[329.3 - 910.5]ng/ml，P = 0.005）。血清钙卫蛋白水平与PsA病程（rho = 0.280，P = 0.013）和平均cIMT（rho = 0.249，P = 0.038）相关。使用LASSO回归分析，从总共19个变量中筛选出Ln-钙卫蛋白水平（OR：3.38，95%CI[1.37，9.47]；P = 0.026）和PsA病程（OR：1.09，95%CI[1.01，1.18]；P = 0.013）。由Ln-钙卫蛋白和PsA病程构建预测CP存在的模型，其受试者工作特征（ROC）曲线下面积为0.744，（95%CI[0.59，0.80]，P = 0.037）。
PsA患者血清钙卫蛋白水平与CP的存在相关。需要进一步研究来证实该途径是否与PsA中的心血管事件相关。
